Drug Discovery Platforms: Connecting Research with Therapeutic Innovation

Drug discovery moves from defining a disease mechanism, through target validation, drug identification and candidate testing, down to the point of clinical development. A potential molecule needs to be active on a biological target, selective and have properties that are conducive to development. Evidence is created in different ways during each of the stages and by different specialist teams. Digital platforms connect information by organizing research data and linking computational analysis with laboratory data. They assist scientists in determining the performance of candidates and where to investigate further.

An integrated environment should not be just a repository of datasets. Researchers need to determine the source of information, the conditions under which an experiment was performed, and the connection between the new observation and the previous ones. A screening result is more useful when looked at along with the protocol used for the assay, the identity of the compounds used and the biological model used. Linking these details aids teams to evaluate evidence and prioritize questions for consideration.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Integrated Research Is Changing Drug Discovery Workflows

One of the major shifts in the market is from stand-alone research applications to connected discovery environments. Different systems can be used for compound registration, high-throughput screening, electronic laboratory notebooks and assay analysis in laboratories. If information is split, researchers' time is wasted trying to reconcile records and confirm sample identities. A consistent view of a compound's progress from initial screening to later experiments is provided by connected platforms.

The amount of experimental information generated during early discovery has grown with the increase in high-throughput screening. Large compound libraries are assessed by automated instruments, and high-content imaging records changes in cellular structure and behavior. Annotations and metadata on assay protocols, biological models and experimental conditions are needed in a consistent manner to facilitate research. Without context, measurements might be hard to compare.

The linkage between computational and experimental research is also growing. The use of molecular modeling and cheminformatics assists in understanding binding interactions, comparing chemical structures and determining modifications that should be tested. Bioinformatics helps in understanding biological pathways and possible therapeutic targets. As results of analyses are related to the findings of the assays, an analysis can inform the next research question. During the candidate evaluation process, the computational insight and the laboratory evidence feed back to each other.

Strengthening Data Integrity and Research Coordination

Data quality poses a significant challenge, as discovery information is generated in different ways and recorded in various formats. Comparisons might not be trustworthy because of variations in terminology, sample identifiers, and protocols. The issue is addressed at entry via shared data standards, controlled vocabularies and structured metadata. A properly configured platform will make it easy to work with consistent records, but there will still be details that are specific to the experiments that can be captured.

Instruments and existing applications from different vendors may have incompatible formats, interfaces or both, making integration difficult. A modular architecture allows for replacing individual systems without disrupting the lab and has documented interfaces. Current tools can be integrated in phases, and the current workflows can be retained. Laboratory scientists should be involved in configuration in order to ensure that digital processes are faithful to actual laboratory practice.

Research data need to be protected due to the valuable intellectual property, findings and information shared with external partners that are contained in discovery programs. Records are protected with role-based permissions, encryption, audit trails, and secure collaboration spaces, while enabling authorized teams to collaborate. Governance policies should define access permissions, access logs and future access restrictions and when information can be shared or kept. Clear controls enable accountability but do not impede collaboration.

Advancing Discovery through Connected Innovation

An optimized drug discovery platform enables a research team to prioritize targets and candidate compounds based on information from various stages of drug discovery. Having screening results, molecular properties and biological data in one place allows easier comparison of candidates along the relevant criteria. When scientists know where evidence is established, they also know where they have uncertainties and what experiments might answer these questions. The goal is not to make drug discovery easier, but to simplify the evidence to be evaluated and used.

The impact is felt throughout the research organization. Progress can be tracked by project leaders, and dependencies between experiments can be understood. The exchange of results between biologists, medicinal chemists and data scientists can be facilitated with more uniform records. Information and decision-making are tracked as programs progress toward development. Role-specific views offer relevant access, without losing track of research.

Making science relevant to decision-makers, like pharmaceutical scientists, is an opportunity to link up the science and to maintain an evidence-based process. A drug discovery platform provides infrastructure for collaboration, traceability and informed prioritization. It collaborates closely with laboratory work and effective data management practices, allowing teams to interpret results, concentrate experimental efforts on pertinent questions, and filter and develop candidates they support.